Next Article in Journal
Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition
Previous Article in Journal
Improved Labeling of Pancreatic Islets Using Cationic Magnetoliposomes
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessArticle
J. Pers. Med. 2018, 8(2), 13; https://doi.org/10.3390/jpm8020013

Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations

1
KEW Inc., 840 Memorial Drive, Cambridge, MA 02139, USA
2
Sanofi US, 270 Albany Street, Cambridge, MA 02139, USA
*
Author to whom correspondence should be addressed.
Received: 27 January 2018 / Revised: 29 March 2018 / Accepted: 6 April 2018 / Published: 9 April 2018
Full-Text   |   PDF [2535 KB, uploaded 3 May 2018]   |  

Abstract

Oncogenic epidermal growth factor receptors (EGFRs) can recruit key effectors in diverse cellular processes to propagate oncogenic signals. Targeted and combinational therapeutic strategies have been successfully applied for treating EGFR-driven cancers. However, a main challenge in EGFR therapies is drug resistance due to mutations, oncogenic shift, alternative signaling, and other potential mechanisms. To further understand the genetic alterations associated with oncogenic EGFRs and to provide further insight into optimal and personalized therapeutic strategies, we applied a proprietary comprehensive next-generation sequencing (NGS)-based assay of 435 genes to systematically study the genomic profiles of 1565 unselected solid cancer patient samples. We found that activating EGFR mutations were predominantly detected in lung cancer, particularly in non-small cell lung cancer (NSCLC). The mutational landscape of EGFR-driven tumors covered most key signaling pathways and biological processes. Strikingly, the Wnt/β-catenin pathway was highly mutated (48 variants detected in 46% of the EGFR-driven tumors), and its variant number topped that in the TP53/apoptosis and PI3K-AKT-mTOR pathways. Furthermore, an analysis of mutation distribution revealed a differential association pattern of gene mutations between EGFR exon 19del and EGFR L858R. Our results confirm the aggressive nature of the oncogenic EGFR-driven tumors and reassure that a combinational strategy should have advantages over an EGFR-targeted monotherapy and holds great promise for overcoming drug resistance. View Full-Text
Keywords: NGS; EGFR-driven cancers; signaling; genomic profiling; biomarkers; Wnt/β-catenin pathway NGS; EGFR-driven cancers; signaling; genomic profiling; biomarkers; Wnt/β-catenin pathway
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Jiang, J.; Protopopov, A.; Sun, R.; Lyle, S.; Russell, M. Genomic Profiling on an Unselected Solid Tumor Population Reveals a Highly Mutated Wnt/β-Catenin Pathway Associated with Oncogenic EGFR Mutations. J. Pers. Med. 2018, 8, 13.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top